← All trials
NCT02417961
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 27, 2015
- Primary completion
- Mar 14, 2016
- Completion date
- Mar 14, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 162
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- Pulmonary Research Institute of Southeast MichiganOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.